Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status
J. S. Gerke, M. F. Orth, Y. Tolkach, L. Romero-Perez, F. S. Wehweck, S. Stein, J. Musa, M. M. L. Knott, T. L. B. Hoelting, J. Li, G. Sannino, A. Marchetto, S. Ohmura, F. Cidre-Aranaz, M. Mueller-Nurasyid, , T. G. P. Grunewald
This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.
bioRxiv · Feb 10, 2019Cancer Biology